Survodutide – 10mg

Survodutide is a synthetic dual receptor agonist simultaneously targeting glucagon like peptide-1 (GLP-1) and glucagon receptors, the same receptor combination as Mazdutide, sharing the GLP-1/glucagon co-activation mechanism that distinguishes this compound class from GLP-1/GIP dual agonists. Developed by Boehringer Ingelheim, Survodutide has progressed through clinical development with a documented Phase 2 trial programme examining obesity and metabolic dysfunction associated steatohepatitis (MASH) contributing an emerging human clinical literature base that positions it alongside Mazdutide as one of the more clinically advanced GLP-1/glucagon dual agonist research compounds currently available. iLab Pharma’s formulation supplies 10mg as a lyophilized vial, preserving peptide structural integrity and potency across storage conditions until reconstitution.

The GLP-1 and glucagon receptor co activation mechanism shared by Survodutide and Mazdutide produces complementary effects across distinct tissue targets. GLP-1 receptor activation drives glucose dependent insulin secretion, pancreatic glucagon suppression, gastric emptying delay, and central nervous system satiety signaling. Glucagon receptor co activation stimulates hepatic glucose output regulation, thermogenic energy expenditure through brown adipose tissue activation, and lipolytic activity in white adipose tissue. Mechanisms that operate in parallel with rather than opposition to the GLP-1 pathway in the context of overall metabolic regulation. This combined receptor profile has generated specific research interest in MASH and non alcoholic fatty liver disease contexts, where glucagon receptor mediated hepatic lipid metabolism effects complement GLP-1’s insulin sensitizing activity in liver tissue.

The distinction between Survodutide and Mazdutide as research compounds lies in their clinical development trajectories and structural characteristics rather than their receptor targets. Survodutide’s Boehringer Ingelheim development program has generated specific Phase 2 clinical data in MASH. A hepatic research context where its glucagon receptor mediated liver lipid metabolism activity has been a primary investigation focus. Mazdutide’s Innovent Biologics development program has focused primarily on obesity endpoints in Asian patient populations. These divergent clinical investigation pathways make the two compounds complementary rather than redundant research tools despite their shared receptor mechanism, and CSD’s stocking of both allows researchers to source the complete GLP-1/glucagon dual agonist compound family from a single verified Canadian supplier.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and iLab Pharma’s Survodutide meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside Mazdutide and GLP-1 agonist compounds in comparative GLP-1/glucagon receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.